Company Analysis
Sign in

Takeda Pharmaceutical Company Limited (TAK)

NYSE: TAK · Pharmaceutical Preparations · Tokyo, JP · filing with the SEC since 2007
Full chart Alerts Compare
Grade5.7
◀ Past 7.8● Present 4.9▶ Future 4.4
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue¥4.58T+7.5%
Net income¥108.1B-25.0%
Earnings per share¥67.23-26.3%
Operating cash flow¥1.06T+47.6%
Cash¥385.1B-15.9%
Debt¥4.52T-6.8%
Shareholders’ equity¥6.94T-4.6%
Shares, diluted1.61B+1.6%
Return on equity1.6%
The recordfrom its filings
Filings in 2026140
Newest filingNov 5 · 4
Annual reportJun 17, 2026
Quarterly reportn/a
Next report due20-F by Jul 29
Insider sales, 12 months$15.2M
Insider buys, 12 months$0.00
Patents granted1,182
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in JPY. Nothing here is a forecast.

News

Nov 5, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 15, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton TAK · research, not advice